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Preface to the English edition
This English edition was made based on the Japanese
version published as a book in 2014. Our policy in com-
piling this edition was to attempt not to include new evi-
dence that emerged since the publication of the Japanese
version so as to maintain consistency of the two editions.
However, for some particularly important issues, we pro-
vided additional comments and new references reflecting
the new evidence.
Preface
Version 4 of the Japanese Gastric Cancer Treatment
Guidelines was completed in May 2014, incorporating new
evidence that includes those delivered as a quick bulletin in
the website of the Japan Gastric Cancer Association after
publication of the previous version. It remains largely
conformed to the textbook style, but a new section con-
sisting of clinical questions and answers (Q&A) was added
to address some important clinical issues for which hard
evidence is unavailable.
To compile this version, the guideline committee nom-
inated several working groups, each assigned to make
relevant contributions to unsolved issues on the following
topics: (1) surgery and lymphadenectomy for junctional
cancer, (2) clinical pathway, (3) follow-up after curative
surgery, (4) treatment of technically resectable metastatic
cancer, (5) risk calculation for surgical intervention and (6)
treatment of cancer of the gastric remnant. Of these, ten-
tative consensuses were reached on the first three topics
that were included as new sections in the text, whereas
further discussion was deemed necessary for the last two
topics. The clinical importance of the fourth topic and lack
of hard evidence related to that topic prompted the com-
mittee to establish a Q and A section to provide tentative
best answers to important clinical questions on technically
resectable metastatic cancer.
Major points of revision in the current version are listed
below:
1. The section on types and definitions of gastric surgery
has been revised.
2. An algorithm showing the tentative standard of the
extent of lymphadenectomy that can be recommended
for junctional cancer less than 4 cm in diameter has
been presented.
3. Laparoscopic distal gastrectomy for clinical stage I
cancer was upgraded from an investigational treatment
to an option in general practice.
4. Chemotherapeutic regimens were classified into three
recommendation categories based on the level of
evidence and consensus among the committee members.
5. A revisionwasmade to the definitionof curative resection
among tumors of expanded indication for endoscopic
resection. Additional descriptions were given on the
biopsy-derived scar and component of ‘‘muc’’ in the
submucosa of the endoscopy-resected specimen.
6. Clinical questions were raised on treatment strategy for
technically resectable metastatic cancer and chemother-
apy for patients for whom evidence-based standard
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treatment may not be applicable, and the tentative but
best possible answers were provided.
7. Exemplary samples of the clinical pathway for man-
agement of patients who underwent gastrectomy and
the follow-up schedule after surgery for gastric cancer
were presented.
The description of tumor status (T/N/M and stage) in
this guideline remains to be based on the third English
edition of the Japanese Classification of Gastric Car-
cinoma [1], which is identical to that in the 7th edition
of the International Union Against Cancer (UICC)/
TNM.
Treatments
Algorithm of standard treatments to be
recommended in clinical practice
The algorithm is shown in Fig. 1.
Investigational treatments
The following treatments show promise but are as yet to be
established as the standard. They should be prospectively
evaluated in appropriate clinical research settings. Patient
consent for investigational treatments should be sought and
the rationale behind them given.
The following constitute investigational treatments:
– Endoscopic submucosal dissection under the expanded
criteria [see ‘‘Tumors indicated for endoscopic resection
as an investigational treatment (expanded indication)’’].
– Laparoscopic surgery for advanced cancer and those in
need of total gastrectomy.
– Local tumor resection.
– Neoadjuvant chemotherapy.




Types and definitions of gastric surgery
Curative surgery
Standard gastrectomy Standard gastrectomy is the prin-
cipal surgical procedure performed with curative intent. It
involves resection of at least two-thirds of the stomach with
a D2 lymph node dissection.
Non-standard gastrectomy In non-standard gastrectomy,
the extent of gastric resection and/or lymphadenectomy is
altered according to tumor stages.
Fig. 1 Algorithm of standard
treatments
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Modified surgery The extent of gastric resection and/or
lymphadenectomy is reduced (D1, D1?, etc.) compared to
standard surgery.
Extended surgery (1) Gastrectomy with combined resection
of adjacent involved organs. (2) Gastrectomy with exten-
ded lymphadenectomy exceeding D2.
Non-curative surgery
Palliative surgery Serious symptoms such as bleeding or
obstruction may develop in a patient with advanced/
metastatic gastric cancer. Surgery to relieve symptoms
may then be considered an option, and palliative gas-
trectomy or gastrojejunostomy is selected depending on
the resectability of the primary tumor and/or surgical
risks. Stomach-partitioning gastrojejunostomy has been
reported to result in superior function compared to simple
gastrojejunostomy [2].
Reduction surgery The role of gastrectomy is unclear in
patients with metastatic gastric cancer in the absence of
urgent symptoms such as bleeding or obstruction. Reduc-
tion surgery aims to prolong survival or to delay the onset
of symptoms by reducing tumor volume.
(Additional comments in this English edition) No evidence
in support of reduction surgery was found in an interna-
tional cooperative randomized controlled trial (REGATTA,
JCOG0705/KGCA01 [3]).
Extent of gastric resection
Surgery for gastric cancer
Surgery for gastric cancer is defined as follows in the order
of the stomach volume to be resected.
– Total gastrectomy Total resection of the stomach
including the cardia and pylorus.
– Distal gastrectomy Stomach resection including the
pylorus. The cardia is preserved. In the standard
gastrectomy, two-thirds of the stomach is resected.
– Pylorus-preserving gastrectomy (PPG) Stomach resec-
tion preserving the upper third of the stomach and the
pylorus along with a portion of the antrum.
– Proximal gastrectomy Stomach resection including the
cardia (esophagogastric junction). The pylorus is
preserved.
– Segmental gastrectomy Circumferential resection of the
stomach preserving the cardia and pylorus.
– Local resection.
– Non-resectional surgery (bypass surgery, gastrostomy,
jejunostomy).
Determination of gastric resection
Resection margin A sufficient resection margin should be
ensured when determining the resection line in gastrectomy
with curative intent. Proximal margin of at least 3 cm is
recommended for T2 or deeper tumors with an expansive
growth pattern (types 1 and 2) and 5 cm for those with an
infiltrative growth pattern (types 3 and 4). When these rules
cannot be observed, it is advisable to examine the proximal
resection margin by frozen section. For tumors invading
the esophagus, a 5-cm margin is not necessarily required,
but frozen section examination of the resection line is
desirable to ensure an R0 resection.
For T1 tumors, a gross resection margin of 2 cm should
be obtained. When the tumor border is unclear, preopera-
tive endoscopic marking by clips of the tumor border based
on biopsy results will be helpful for decision making
regarding the resection line.
Selection of gastrectomy The standard surgical procedure
for clinically node-positive (cN?) or T2-T4a tumors is either
total or distal gastrectomy. Distal gastrectomy is selected
when a satisfactory proximal resectionmargin (see above) can
be obtained. Pancreatic invasion by tumor requiring pancre-
aticosplenectomy necessitates total gastrectomy regardless of
the tumor location. Total gastrectomy with splenectomy
should be considered for tumors that are located along the
greater curvature and harbor metastasis to no. 4sb lymph
nodes, even if the primary tumor could be removed by distal
gastrectomy. For adenocarcinoma located on the proximal
side of the esophagogastric junction, esophagectomy and
proximal gastrectomy with gastric tube reconstruction should
be considered, similarly to surgery for esophageal cancer.
For cT1cN0 tumors, the following types of gastric
resection can be considered according to tumor location.
– Pylorus-preserving gastrectomy (PPG): for tumors in
the middle portion of the stomach with the distal tumor
border at least 4 cm proximal to the pylorus.
– Proximal gastrectomy: for proximal tumors where more
than half of the distal stomach can be preserved.
– Segmental gastrectomy and local resection under
sentinel navigation are still regarded as investigational
treatments.
Lymph node dissection
Extent of lymph node dissection
The extent of systematic lymphadenectomy is defined as
follows according to the type of gastrectomy conducted.
When the extent of lymphadenectomy performed does not
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fully complywith the D level criteria, the lymph node station
that has been additionally resected or left in situ could be
recorded as in the following examples: D1 (?No. 8a), D2
(-No. 10). However, when sending data to the nationwide
database, the D level needs to be strictly decided upon and
should be downgraded if resection of any of the lymph node
stations that should have been resected was omitted.
Total gastrectomy (Fig. 2)
D0: Lymphadenectomy less than D1.
D1: Nos. 1–7.
D1?: D1 ? No. 8a, 9, 11p.
D2: D1 ? No. 8a, 9, 10, 11p, 11d, 12a.
For tumors invading the esophagus, D1? includes:
No. 110*, D2 includes No. 19, 20, 110 and 111.
Distal gastrectomy (Fig. 3)
D0: Lymphadenectomy less than D1.
D1: No. 1, 3, 4sb, 4d, 5, 6, 7
D1?: D1 ? No. 8a, 9
D2: D1 ? No. 8a, 9, 11p, 12a.
Pylorus-preserving gastrectomy (Fig. 4)
D0: Lymphadenectomy less than D1.
D1: No. 1, 3, 4sb, 4d, 6, 7.
D1?: D1 ? No. 8a, 9.
Proximal gastrectomy (Fig. 5)
D0: Lymphadenectomy less than D1.
D1: No. 1, 2, 3a, 4sa, 4sb, 7.
D1?: D1 ? No. 8a, 9, 11p.
For tumors invading the esophagus, D1 ? includes No.
110*.
*No. 110 lymph nodes (lower thoracic para-esophageal
nodes) in gastric cancer invading the esophagus are those
attached to the lower part of the esophagus that is removed
to obtain a sufficient resection margin.
Fig. 2 The extent of lymphadenectomy after total gastrectomy. The
numbers correspond to the lymph node station as defined in the
Japanese Classification of Gastric Carcinoma (1). Complete dissec-
tion of the nodes in blue denotes D1 dissection, the nodes in orange
D1? and the nodes in red D2
Fig. 3 The extent of lymphadenectomy after distal gastrectomy. The
numbers correspond to the lymph node station as defined in the
Japanese Classification of Gastric Carcinoma (1). Complete dissec-
tion of the nodes in blue denotes D1 dissection, the nodes in orange
D1? and the nodes in red D2
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Indications for lymph node dissection
In principle, a D1 or a D1? lymphadenectomy is indicated
for cT1N0 tumors and D2 for cN? or cT2-T4 tumors. Since
the pre- and intraoperative diagnoses of lymph node metas-
tases remain unreliable, a D2 lymphadenectomy should be
performed whenever nodal involvement is suspected.
D1 lymphadenectomy A D1 lymphadenectomy is indi-
cated for T1a tumors that do not meet the criteria for EMR/
ESD, and for cT1bN0 tumors that are histologically of
differentiated type and 1.5 cm or smaller in diameter.
D1? lymphadenectomy A D1? lymphadenectomy is
indicated for cT1N0 tumors other than the above.
D2 lymphadenectomy A D2 lymphadenectomy is indi-
cated for potentially curable T2-T4 tumors as well as
cT1N? tumors. The role of splenectomy for complete
resection of Nos. 10 and 11 nodes had long been an issue of
controversy, and the final results of a randomized trial
(JCOG 0110) are awaited. In the meantime, complete
clearance of No. 10 nodes by splenectomy should be
considered for potentially curable T2-T4 tumors invading
the greater curvature of the upper stomach.
(Additional comments in this English edition) The ran-
domized trial (JCOG 0110) was concluded and revealed
non-inferiority of spleen preservation in terms of overall
survival. Splenectomy should not be performed unless the
primary T2-T4 tumor either directly invades the spleen or
is located in the greater curvature of the upper stomach [4].
D2? lymphadenectomy Gastrectomy with extended
lymphadenectomy beyond D2 is classified as a non-stan-
dard gastrectomy. Its role has been discussed as follows.
– The benefit of prophylactic para-aortic lymphadenec-
tomy was denied by the randomized trial, JCOG 9501
[5].
– Although a R0 resection may be possible for tumors
with para-aortic nodal involvement without other non-
curative factors, the prognosis of this population is
poor. Nevertheless, neoadjuvant chemotherapy fol-
lowed by D2? is a promising option (refer to CQ1).
– The role of No. 14v lymphadenectomy in distal gastric
cancer is controversial. Dissection of No. 14v had been
a part of D2 gastrectomy defined by the 13th edition of
the Japanese Classification of Gastric Carcinoma, but
was excluded from the previous version (version 3) of
the Japanese Gastric Cancer Treatment Guidelines and
remains that way in the current version. However, D2
(?No. 14v) may be beneficial for patients who are
suspected to harbor metastasis to the No. 6 nodes.
– Involvement of No. 13 nodes is defined as M1 in the
current version. However, D2 (?No. 13)
Fig. 5 The extent of lymphadenectomy after proximal gastrectomy.
The numbers correspond to the lymph node station as defined in the
Japanese Classification of Gastric Carcinoma (1). Complete dissec-
tion of the nodes in blue denotes D1 dissection and the nodes in
orange D1?
Fig. 4 The extent of lymphadenectomy after pylorus-preserving
gastrectomy. The numbers correspond to the lymph node station as
defined in the Japanese Classification of Gastric Carcinoma (1).
Complete dissection of the nodes in blue denotes D1 dissection and
the nodes in orange D1?
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lymphadenectomy may be an option in a potentially
curative gastrectomy for tumors invading the duode-
num [6].
Junctional cancer
In the Japanese Classification of Gastric Carcinoma,
junctional cancer has been defined as cancer (adenocar-
cinoma or squamous cell carcinoma) with its center
located within 2 cm of the esophago-gastric junction.
There is no consensus over the type of resection and the
extent of lymphadenectomy that could be a standard of
care for this category. In 2012–2013, the Japanese Gastric
Cancer Association and Japan Esophageal Society joined
forces to conduct a nationwide surveillance of junctional
cancer of B4 cm diameter, and retrospective data of 3177
patients operated on between 2001 and 2010 were col-
lected from 273 institutions. An algorithm showing the
tentative standard in the extent of lymphadenectomy
based on the tumor location, histology and T-categories
was constructed based on this surveillance (Fig. 6). The
anatomical border between Nos. 19 and 20 and among
Nos. 110, 111 and 112 cannot be defined clearly.
Therefore, lower mediastinal nodes and hiatal nodes were
each treated as one lymph node station in the current
analysis. Dissection of No. 3b can be omitted when per-
forming proximal gastrectomy. A prospective phase II




It is reported that preservation of the hepatic branch of the
anterior vagus and/or the celiac branch of the posterior
vagus contributes to improving postoperative quality of life
through reducing post-gastrectomy gallstone formation,
diarrhea and/or weight loss. In case of PPG, the hepatic
branch should be preserved to maintain the pyloric function.
Omentectomy
Removal of the greater omentum is usually integrated in
the standard gastrectomy for T3 (SS) or deeper tumors. For
T1/T2 tumors, the omentum more than 3 cm away from the
gastroepiploic arcade may be preserved.
Bursectomy
For tumors penetrating the serosa of the posterior gastric
wall, bursectomy (removal of the inner peritoneal surface of
the bursa omentalis) may be performed with the aim of
removingmicroscopic tumor deposits in the lesser sac. There
is no evidence that bursectomy reduces peritoneal or local
recurrence, and it should be avoided in T1/T2 tumors to
prevent injury to the pancreas and/or adjacent blood vessels.
A small-scale randomized controlled trial recently sug-
gested a survival benefit for bursectomy in T3/T4a tumors
Fig. 6 Algorithm showing the
tentative standard in the extent
of lymphadenectomy for
junctional cancer based on the
tumor location, histology and
T-categories
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[7]. A large-scale multi-institutional randomized trial to
address this issue (JCOG 1001) was subsequently launched
and has completed accrual.
Combined resection of adjacent organ(s)
For tumors in which the primary or metastatic lesion directly
invades adjacent organs, combined resection of the involved
organ may be performed in order to obtain an R0 resection.
Approaches to the lower esophagus
For gastric cancers invading less than 3 cm of the distal
esophagus, a transhiatal abdominal approach is recom-
mended [8]. Where a greater length of esophagus is
involved, a transthoracic approach should be considered if
the surgery is potentially curative.
Laparoscopic surgery
Laparoscopic surgery can be considered an option in gen-
eral clinical practice to treat cStage I cancer that is indi-
cated for distal gastrectomy. In the 2014 version of the
guidelines by the Japan Society for Endoscopic Surgery,
distal gastrectomy by the laparoscopic approach has been
recommended for cStage I cancer (rated recommendation
B). These decisions reflect the fact that the safety of the
laparoscopic approach was proven in a prospective phase II
study (JCOG0703) that involved only certified surgeons
with sufficient experience [9] and that superiority in terms
of short-term outcome has been reported through small-
scale randomized trials and meta-analyses. However, sur-
geons will have to be aware that the learning-curve issue
exists, and the indication for this approach should be
decided discreetly in each institution based on the expertise
of the staff members that participate in this type of surgery.
Data regarding the long-term outcome are yet to be
available, and results of pivotal phase III studies conducted
in Japan (JCOG0912 [10]) and Korea (KLASS01 [11]) are
awaited. As for more advanced cancer, there is currently no
evidence to recommend a laparoscopic approach since
randomized trials to look at safety and long-term outcome
are currently ongoing (JLSSG0901, KLASS02).
Regarding total gastrectomy by this approach, no
prospective trial has been reported. Thus, laparoscopic total
gastrectomy has been rated by the guidelines of the Japan
Society for Endoscopic Surgery (2014) as recommendation
C1 (may be considered for a patient in need of total gastrec-
tomy, but no scientific evidence in support of the procedure is
currently available). Those who consider challenging the
procedure should plan to do so with sufficient caution since
postoperative complications were reported to be significantly
more frequent in the first year of its introduction.
When conducting gastrectomy by the laparoscopic
approach, informed consent should be obtained from all
patients after providing sufficient information, including
the lack of data regarding long-term consequences.
Reconstruction after gastrectomy
The following reconstruction methods are usually
employed. Each has advantages and disadvantages. Func-





– Double tract method.
Distal gastrectomy
– Billroth I gastroduodenostomy.








– Double tract method.
Endoscopic resection
Methods of endoscopic resection
Endoscopic mucosal resection (EMR)
The lesion, together with the surrounding mucosa, is lifted
by submucosal injection of saline (normo- or hypertonic)
and removed using a high-frequency steel snare.
Endoscopic submucosal dissection (ESD)
The mucosa surrounding the lesion is circumferentially
incised using a high-frequency electric knife (usually
Japanese gastric cancer treatment guidelines 2014 (ver. 4) 7
123
insulation-tipped), and the submucosal layer is dissected
from the proper muscle layer.
Handling of endoscopically resected specimens
Handling of resected specimens
The resected specimens should be handled according to the
rules described in the Japanese Classification of Gastric
Carcinoma [1].
Definition of differentiated-type and undifferentiated-type
carcinoma
The tumor biopsy specimens and endoscopically resected
tumors are histologically classified into either the differ-
entiated or undifferentiated type. The former includes
papillary adenocarcinoma (pap) and tubular adenocarci-
noma (tub1, tub2), and the latter includes poorly differen-
tiated adenocarcinoma (por1, por2) and signet-ring cell
carcinoma (sig). Endoscopic dissection should be defined
as non-curative if mucinous adenocarcinoma (muc) was
found in the submucosal layer, regardless of whether it is
considered to derive from the differentiated or undiffer-
entiated type.
Histological predominance and intratumoral ulcerative
findings (UL)
A tumor consisting of components of both differentiated-
and undifferentiated-type carcinoma is nevertheless clas-
sified into one of the two types according to the quantita-
tive predominance. In addition, when more than one
histological type is found in a tumor, all histological types
are to be recorded in the order of quantitative predomi-
nance, e.g., tub2[ tub1. Diagnosis of UL(?) is principally
made based on the histological evidence of ulcerative
findings. However, endoscopic and/or radiological evi-
dence should also be taken into consideration when making
a conclusive diagnosis. A biopsy-derived scar is usually
observed histologically as fibrosis restricted to small areas
just beneath the muscularis mucosae. However, if it cannot
be discriminated from the ulcer scar, it should be classified
as UL(?).
Indication for endoscopic resection (Fig. 7)
Principles of indication
Endoscopic resection is considered for tumors that have a
very low possibility of lymph node metastasis and are
suitable for en-bloc resection.
Fig. 7 Algorithm showing
treatment of early gastric cancer
according to the histopathologic
findings of the specimens
resected by ESD
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Since compilation of the first version of this guideline,
two independent sets of indications for the endoscopic
resection have been provided: an absolute indication for
standard EMR/ESD and an expanded indication for ESD to
be considered as an investigational treatment. The evidence
regarding curability of the latter technique remains insuf-
ficient, and the procedure should be offered with caution.
Tumors indicated for endoscopic resection as a standard
treatment (absolute indication)
EMR or ESD is indicated as a standard treatment for the
following tumor.
– A differentiated-type adenocarcinoma without ulcera-
tive findings [UL(-)], of which the depth of invasion is
clinically diagnosed as T1a and the diameter is B2 cm.
Tumors indicated for endoscopic resection
as an investigational treatment (expanded indication)
Tumors of the following categories have very low possi-
bility of lymph node metastasis when they are not
accompanied with lymphovascular infiltration [ly(-),
v(-)] and could be indicated for endoscopic resection
[12, 13]. To avoid incomplete dissection, ESD rather than
EMR should be performed. Since evidence on long-term
survival is currently lacking, however, endoscopic treat-
ment for these lesions should be considered investigational
until trials such as JCOG0607 turn out to be positive.
Tumors clinically diagnosed as T1a and
(a) Of differentiated-type, UL(-), but[2 cm in
diameter.
(b) Of differentiated-type, UL(?), and B3 cm in
diameter.
(c) Of undifferentiated-type, UL(-), and B2 cm in
diameter.
Local recurrence after EMR/ESD
Local mucosal recurrence after EMR/ESD for tumors that
had fulfilled the absolute indication could be considered to
meet the criteria for expanded indication and may be
treated by another ESD. However, given paucity of the
evidence in terms of long-term survival, repeat ESD should
be also considered as investigational.
Curability of endoscopic resection
Meticulous pathologic examination of the resected speci-
men is mandatory. Curability needs to be assessed based on
both the results of the pathologic examination and facts
based on the accumulated data. Two factors should be
considered for curability assessment: completeness of the
primary tumor removal and nil possibility of lymph node
metastasis.
Curative resection
The resection is determined as curative when all of the
following conditions are fulfilled: en bloc resection, tumor
size B2 cm, histologically of differentiated type, pT1a,
negative horizontal margin (HM0), negative vertical mar-
gin (VM0) and no lymphovascular infiltration (ly(-),
v(-)).
Curative resection for tumors of expanded indication
The resection is considered as curative when all of the
following conditions are fulfilled:
En bloc resection, HM0, VM0, ly(-), v(-), and
(a) Tumor size[2 cm, histologically of differentiated
type, pT1a, UL(-).
(b) Tumor size B3 cm, histologically of differentiated
type, pT1a, UL(?).
(c) Tumor size B2 cm, histologically of undifferenti-
ated type, pT1a, UL(-).
(d) Tumor size B3 cm, histologically of differentiated
type, pT1b (SM1,\500 micron from the muscularis
mucosae).
As the evidence is still insufficient for differentiated
type tumors accompanied with some areas of undifferen-
tiated type histology, the following resections are regarded
as non-curative for the time being, and addition of surgical
treatments should be recommended.
– Areas of undifferentiated type carcinoma exceed 2 cm
in the above (a).
– Undifferentiated type component in the part that had
invaded the submucosa in the above (d).
A new rule in the current version is that if a component
of undifferentiated type carcinoma was found in the above
(b) but was not the predominant histological type, risk of
nodal metastasis is estimated to be low [14], and the
endoscopic resection will be regarded as curative.
Non-curative resection
Resection that does not satisfy any of the above criteria is
considered non-curative.
Japanese gastric cancer treatment guidelines 2014 (ver. 4) 9
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Treatments after endoscopic resection
Treatments after curative resection
Follow-up with annual or biannual endoscopy is
recommended.
Treatments after curative resection for tumors of expanded
indications
Follow-up with abdominal ultrasonography or CT scan as
well as annual or biannual endoscopy is recommended.
In case of either ‘‘Treatments after curative resection’’ or
‘‘Treatments after curative resection for tumors of expan-
ded indications,’’ it has been recommended that Heli-
cobacter pylori be examined and, if positive, be eradicated.
However, some studies showed that Helicobacter eradica-
tion after ER had no impact on the occurrence of meta-
chronous cancer. Further investigations regarding this issue
are warranted.
Treatment after non-curative resection
Surgical treatment should be performed after non-curative
resection. However, as the following cases actually carry
very low risk for harboring lymph node metastasis, non-
surgical treatments such as repeated ESD, endoscopic
coagulation using a laser or argon-plasma coagulator, or
close observation expecting a burn effect of the initial ESD
could be proposed as alternatives and delivered upon the
patient’s informed consent.
– En bloc resection of a differentiated type carcinoma
with positive horizontal margin (HM1) as the only non-
curative factor.
– Piecemeal resection of a differentiated type carcinoma
satisfying all other criteria.
When these cases come from the category (b) or (d) of
the ‘‘Curative resection for tumors of expanded indica-
tion,’’ the size of the residual mucosal lesion should be re-
assessed by endoscopy. If the sum of the lengths of the
resected and residual lesions exceeds 3 cm, surgery is
indicated. When the positive horizontal margin or the
piecemeal resection margin involves the part of submu-
cosal invasion in category (d), surgery is indicated.
Chemotherapy
Although recent advances in chemotherapy have achieved
considerable tumor regression in many cases of unre-
sectable/recurrent gastric cancer, these responses have not
ultimately led to complete cure. The median survival time
achieved in clinical trials for the disease at this stage
remains 6–13 months. The current goal of chemotherapy
therefore is to delay the manifestation of disease-related
symptoms and/or to prolong survival. Survival benefit of
chemotherapy has been proven in randomized controlled
trials comparing chemotherapy with best supportive care
in patients with unresectable gastric cancer with perfor-
mance status (PS) of 0–2. Although very rare, some
patients with advanced disease even survive more than
5 years by chemotherapy alone. Thus, chemotherapy is
the treatment to be primarily considered for unresectable/
recurrent gastric cancer among patients with sufficiently
good PS.
Principles of indication
Chemotherapy is indicated for patients with unresectable or
recurrent disease, or those after non-curative R2 resection,
whose general condition and major organ functions are
preserved: to be specific, patients of PS 0–2, with unre-
sectable T4b disease, extensive nodal disease, hepatic
metastases, peritoneal dissemination or other M1 disease.
Recommendable regimens for Japanese patients
Treatment regimens were classified into the following three
categories according to the degree that the regimen could
be recommended. The recommendation category was
determined by the committee members based on the levels
of reported evidence and, ultimately, through consensus
reached after thorough literature review and discussion
among the members.
– Recommendation category 1: treatment regimens that
are recommended in clinical practice.
Regimens included in this category will need to be
either superior or non-inferior to the standard treatment
in a phase III trial with overall survival as the primary
endpoint. In addition, consensus must be reached
within the committee members on the interpretation
of the phase III study results, availability of the drugs in
Japan and sufficient safety and efficacy data with the
Japanese participants.
– Recommendation category 2: treatment regimens that
could be selected in clinical practice.
Regimens in this category include the following: (1)
those that were found to be superior or non-inferior to
the standard treatment in a phase III trial but failed to
gain sufficient support from the committee members to
be included in category 1; (2) those with sufficient
efficacy and safety data obtained in a phase II trial and
consensus reached among the committee members.
10 Y. Kodera, T. Sano
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– Recommendation category 3: treatment regimens that
cannot be recommended in clinical practice.
Regimens in this category either failed to show
superiority or non-inferiority in terms of overall
survival in a phase III trial or were lacking in sufficient
efficacy/safety data with the Japanese participants.
First-line treatment
HER2 testing Since a trastuzumab-containing regimen
became the standard of care for HER2-positive gastric
cancer, HER2 testing is strongly recommended in all
patients who will undergo chemotherapy for unresectable/
metastatic gastric cancer.
HER2-negative gastric cancer S-1 ? cisplatin combina-
tion is the standard of care (recommendation category 1)
based on the results of two phase III trials conducted in
Japan (SPIRITS trial [15] and JCOG 9912 trial [16]).
Capecitabine ? cisplatin combination is currently one
of standard treatments overseas and was employed as a
control group in global phase III studies, the ToGA trial
[17] and AVAGAST trial [18]. Since subset analyses of the
Japanese participants in these trials have shown safety and
efficacy, this combination can be selected in clinical
practice (recommendation category 2).
S-1 ? docetaxel combination failed to show superiority
to S-1 monotherapy in the primary survival analysis of the
START trial conducted with the Japanese and Korean
participants, but superiority in overall survival was
observed in a reanalysis after clarifying outcome of several
censored cases [19]. This regimen could be selected for a
limited population such as those who wish to be treated at
the outpatient clinic (recommendation category 2).
Irinotecan ? cisplatin and S-1 ? irinotecan combina-
tions are not recommended as the first-line regimen
because they did not show significant superiority over 5-FU
alone and S-1 alone, respectively, in the randomized trials
conducted in Japan [16, 20] (recommendation category 3).
Regarding triplet regimens, efficacy of infusional
5FU ? cisplatin ? docetaxel was proven in the V325
study [21] conducted in the western countries. Given the
excessive toxicity and lack of data for Japanese patients,
this regimen cannot be recommended for general practice
(recommendation category 3). In Japan, a triplet consisting
of S-1, cisplatin and docetaxel (DCS regimen) is currently
being evaluated in a phase III trial, JCOG1013, following
some phase II results. Thus, the DCS regimen currently
needs to be regarded as an investigational treatment.
Evidence is lacking regarding chemotherapy for specific
types of patients such as those with no oral intake, peri-
toneal carcinomatosis (patients with a moderate to high
volume of ascites or bowel obstruction) and the elderly
(refer to CQ5 and CQ6).
(Additional comments in this English edition) Following
the results of the SOX-GC trial [22] and REAL2 trial [23],
S-1 plus oxaliplatin or capecitabine plus oxaliplatin
became options for the first-line chemotherapy and is ten-
tatively rated as recommendation category 2.
HER2-positive gastric cancer IHC3? or FISH positive
patients were eligible for the ToGA trial [17]. In the sub-
group analyses of the trial, survival benefit was more distinct
when IHC3? or FISH positive/IHC2? cohorts were selec-
ted. Thus, trastuzumab-containing regimens will be rec-
ommended for patients with IHC3? or FISH positive/
IHC2? status. Following the results of the ToGA trial, a
combination of trastuzumab, cisplatin and either capecita-
bine or infusional 5FU will be recommended for clinical
practice (recommendation category 1). A phase II trial to
explore trastuzumab combined with triweekly S-1 ? cis-
platin was conducted with promising results. However, this
combination will remain in category 2 at this time because
of the small volume of efficacy and safety data.
Second-line treatment
Second-line treatment is recommended for patients with
sufficient performance status, following several random-
ized trials mentioned below. Monotherapy with any of the
three agents, docetaxel, irinotecan or paclitaxel (weekly
administration), can be recommended (recommendation
category 1).
Randomized trials conducted in Germany [24] and
Korea [25] showed a significant survival advantage of the
second-line treatment (docetaxel or irinotecan) over the
best supportive care. A Japanese phase III trial, WJOG4007
[26], failed to prove superiority in overall survival of
irinotecan over paclitaxel (weekly administration), but did
show median survival time for both groups of approxi-
mately 9 months, which is favorable when compared with
survival data from other trials exploring the second-line
chemotherapy. This could be explained by the fact that a
high proportion of participants in this trial received another
line of treatment (taxanes among patients allocated to the
irinotecan group and irinotecan among those allocated to
the paclitaxel group). Thus, this trial indicates that patients
with good performance status could benefit from the third-
line treatments.
(Additional comments in this English edition) Following the
results of the RAINBOW trial [27] and the REGARD trial
[28], paclitaxel ? ramucirumab emerged as a new standard
of care and was rated as recommendation category 1 in the
second-line setting, while ramucirumab monotherapy was
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rated as recommendation category 2 alongside monothera-
pies with docetaxel, irinotecan or paclitaxel, which were
relegated from recommendation category 1.
Chemotherapy as a general practice
Indication
Indication for chemotherapy should be decided after taking
into consideration the following eligibility criteria.
1. Clinical and pathological diagnosis of gastric cancer
has been obtained.
2. PS of 0–2. Generally speaking, chemotherapy is not
indicated for patients with PS of 3 or 4. Indication for
chemotherapy should be discreetly decided considering
the toxicity and benefit. The safety issue may be of
particular concern when a patient suffers from massive
ascites or overt peritoneal carcinomatosis.
3. Major organ functions are preserved.
4. Patient does not suffer from severe comorbidities.
5. Informed consent has been obtained from the patient.
Methodology
1. Prior to treatment, PS, body weight, clinical symptoms
and laboratory data (including examination for hepatitis
virus) should be checked, and imaging studies such as
computerized tomography (CT) should be performed to
obtain baseline measurements of the lesions.
2. Response to the treatment should be evaluated by
examinations that may include CT, endoscopy and
contrast radiography, followed by comparison with the
baseline data. Tumor shrinkage should be evaluated by
response criteria of the Japanese Classification of
Gastric Carcinoma or Response Evaluation Criteria in
Solid Tumors (RECIST) to decide on whether or not to
continue with the treatment.
3. When continuation of the treatment is deemed onco-
logically feasible, the drug dosage and administration
schedule should be reconsidered taking into account
the adverse events observed in the previous cycle of
treatment. Attention should also be paid to cumulative
adverse events such as skin manifestations, taste
disturbance and neurotoxicity.
4. Chemotherapy for individuals exposed or infected to
hepatitis B virus should be screened, monitored and
treated by referring to ‘‘Chapter 6.3., HBV reactiva-
tion’’ of the Japan Society of Hepatology Guidelines
for the Management of Hepatitis B Virus Infection to
prevent reactivation.
Drugs to be used
The following drugs are used in chemotherapy for gastric
cancer: fluorouracil (5FU), tegafur-gimestat-otastat potas-
sium (S-1), capecitabine, cisplatin, irinotecan, docetaxel,
paclitaxel and trastuzumab. These drugs are to be used
alone or in combination, adhering to the dose and schedule
employed when being evaluated in clinical trials.
(Additional comments in this English edition) Ramu-
cirumab and oxaliplatin can now be added to the list of the
drugs.
Postoperative adjuvant chemotherapy
Postoperative adjuvant chemotherapy is delivered with an
intention to reduce recurrence by controlling residual tumor
cells following curative resection. Various regimens had
been tested in numerous clinical trials in Japan without
producing solid evidence in support of adjuvant chemother-
apy until the efficacy of S-1 was proven in the ACTS-GC
trial [29, 30], a study that secured the place of postoperative
chemotherapy with S-1 as a standard of care (recommenda-
tion category 1). After this, the feasibility of several combi-
nations of anticancer drug with S-1 was explored in the
postoperative setting [31, 32], and some of the combinations
are currently under evaluation in phase III trials. On the other
hand, other phase III evidence in support of postoperative
chemotherapy was established in 2012 by the CLASSIC trial
conducted mainly in Korea [33], in which significant pro-
longation of recurrence-free survival was shown with a
combination of capecitabine and oxaliplatin. However,
oxaliplatin has not been approved for gastric cancer in Japan
as of 2014. Survival benefit of postoperative adjuvant
chemotherapy by combination of S-1 and another cytotoxic
drug, including oxaliplatin, will have to be proven by a
randomized trial with S-1 monotherapy as a control.
(Additional comments in this English edition) Following
the results of J-CLASSIC [34] and SOX-adjuvant trials
[35], capecitabine or S-1 plus oxaliplatin has been
approved as an adjuvant regimen in Japan.
Indications
The patients eligible for the ACTS-GC trial were those
with a tumor of pathological stage II, IIIA or IIIB,
excluding those classified as stage II due to pT1/pN2pN3
status, as defined by the previous 13th edition of the
Japanese Classification of Gastric Carcinoma (2nd English
edition), who had undergone R0 gastrectomy with CD2
lymphadenectomy. The eligibility for postoperative adju-
vant chemotherapy will remain the same in the current
version of the treatment guidelines.
12 Y. Kodera, T. Sano
123
However, in the 14th edition of the Japanese Classifi-
cation of Gastric Carcinoma (3rd English edition) whose
staging scheme is the same as the 7th edition of UICC/
TNM, stage IIA includes pT3(SS)/N0 status, which had
been rated as stage IB in the 13th edition and therefore was
ineligible for the ACTS-GC. In other words, the eligibility
criteria will remain unchanged by excluding this population
as well as the pT1/pN2pN3 population from stage II/III.
Additionally, what has been written in ‘‘Chemotherapy as
a general practice’’ applies also to chemotherapy in the
adjuvant setting except that response to the treatment cannot
be evaluated by imaging modalities until disease recurrence.
Administration schedule
S-1 is to be started within 6 weeks from surgery, after
sufficient recovery from the surgical intervention. A
6-week cycle consisting of 4 weeks of daily oral admin-
istration of S-1 at a dose of 80 mg/m2 followed by 2 weeks
of rest is repeated during the 12 months after surgery (8
cycles). Since postoperative patients are generally more
vulnerable to both hematological and non-hematological
adverse events, appropriate dose reduction and schedule
modification should be considered, including a switch to a
schedule of 2 weeks of administration followed by 1 week
of rest.
Palliative care
Palliative care is an approach that improves the quality of
life of patients and their families facing the problems
associated with life-threatening illness through the preven-
tion and relief of suffering by means of early identification
and impeccable assessment and treatment of pain and other
problems, physical, psychosocial and spiritual (WHO Def-
inition of Palliative Care, 2002). The importance of pallia-
tive care increases incrementally as cancer progresses. The
knowledge and technique to cope with pain, to communicate
and to manage symptoms are required. Methods to accom-
plish these aims include radiotherapy and psychotherapy in
addition to medication. Various clinical studies are on-going
with particular emphasis on pain control.
Clinical pathway after surgery for gastric cancer
It is extremely difficult to establish a clinical pathway for
patients undergoing gastric cancer surgery that is widely
applicable to various surgical procedures and institutions.
However, it is possible to propose some core items based
on which individual pathways could be constructed, and
these could contribute to reducing disparities in surgical
management for gastric cancer. A basic pathway has been
constructed around the timing of some core items such as
removal of the nasogastric tube, initiation of oral fluid
intake, initiation of solid food intake, administration of
antibiotics, stoppage of intravenous fluid administration
and discharge from the hospital (Table 1). This clinical
pathway is applicable to all surgical procedures including
distal, total and proximal gastrectomy regardless of whe-
ther the surgery was performed laparoscopically or by open
approach. However, postoperative management should be
individualized for high-risk patients with severe comor-
bidities that include impaired cardiac, pulmonary, hepatic
or renal functions. Recently, investigators have been
inclined to aim for further shortening of postoperative
hospital stays through the concept of ERAS (enhanced
recovery after surgery), but the value of such programs in
gastric cancer surgery is yet to be defined.
Follow-up surveillance after surgery for gastric
cancer
Follow-up at the outpatient clinic could be helpful so that
the patients can readjust to their lives at home, cope with
postgastrectomy symptoms and overcome the nutritional
Table 1 A common clinical
pathway for distal, total and
proximal gastrectomy
Clinical items Date on the clinical pathway
Removal of nasogastric tube Before or on postoperative day 1
Initiation of oral fluid intake On or after postoperative day 1
Initiation of solid food intake Between postoperative days 2–4
Prophylactic administration of antibiotics Only on the day of operation
Removal of epidural tube Before or on postoperative day 3
Removal of urinary catheter Before or on postoperative day 3
Intravenous fluid administration Until postoperative day 5–7
Removal of intra-abdominal drains Before or on postoperative day 5
Discharge from the hospital Between postoperative days 8–14
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issues. In addition, surveillance for early detection of
recurrence and secondary cancer is usually conducted
according to the level of risk for recurrence, estimated
based on the clinical stages. However, evidence that such
surveillance actually improves survival is lacking. Due to
the paucity of prospective studies that explored follow-up
programs after gastrectomy, it is not possible to make
any recommendation on how often the examinations
should be performed, or even on which examination to
perform. However, some retrospective studies suggest
that CT, measurement of tumor markers (CEA and
CA19-9) and endoscopy are effective to detect recur-
rence, gastric remnant cancer and metachronous multiple
cancer. Tumor markers, when applicable, are apt to rise
2–3 months before metastatic lesions become
detectable by imaging modalities. Models of follow-up
programs for early-stage cancer and advanced cancer are
shown in Tables 2 and 3.
Follow-up should continue for no longer than 5 years
after which patients should be referred to regional general
physicians or should be encouraged to undergo surveillance
examinations provided as a part of health care programs in
their districts or at their places of work. In that aspect,
collaboration among various levels of medical facilities is
needed to provide comprehensive care to gastric cancer
survivors. Ultimately, there remains a need to scientifically
verify the prognostic relevance of postoperative follow-up
programs.
Appendix: clinical questions
CQ1. Should surgery be avoided in patients with gastric
cancer when metastasis to the para-aortic lymph nodes has
been detected?
Answer A multidisciplinary approach including surgery
with para-aortic lymph node dissection could be proposed
when para-aortic lymph node metastases are confined to
the No. 16 a2–b1 region, provided other non-curative
factors are absent.
Para-aortic metastases from gastric cancer are classified
as M1, and surgery with curative intent is not indicated
according to the treatment algorithm of the current guide-
lines (refer to ‘‘Algorithm of standard treatments to be
recommended in clinical practice’’).
Systemic para-aortic lymph node dissection (PAND)
had been attempted in Japan as clinical studies until its
survival benefit was denied in a randomized trial in which
only patients without lymphadenopathy in the para-aortic
region were eligible [5]. However, numerous retrospective
data from patients who underwent PAND are available in
Japan and these almost invariably indicate that (1)
metastases to the para-aortic nodes are pathologically
confirmed in a certain percentage of these patients and (2)
cure was achieved in approximately 10–20 % of the
patients who harbored metastases to the para-aortic nodes.
A similar result was recently reported from a Western
country [36]. Thus, it is not possible to totally deny the
Table 2 Postoperative follow-
up for stage I gastric cancer
patients
Duration after surgery Year: 1 1.5 2 2.5 3 4 5
Month: 1 6 12
Medical examination, PS, body weight s s s s s s s s s
Blood test including tumor markers s s s s s s s s s
CT and/or US s s s s s s
Endoscopy s s s
Examinations to be considered when needs arise: chest X-ray gastrography, barium enema, colonoscopy,
bone scintigram, PET scan
Other surveillance programs should be sought beyond the 5th year
Table 3 Postoperative follow-up for stage II–III gastric cancer patients
Duration after surgery Year: 1 2 2.5 3 3.5 4 4.5 5
Month: 1 3 6 9 12 15 18 21 24
Medical examination, PS, body weight s s s s s s s s s s s s s s s
Blood test including tumor markers s s s s s s s s s s s s s s s
CT and/or US s s s s s s s s
Endoscopy s s s
Examinations to be considered when needs arise: chest X-ray, gastrography, barium enema, colonoscopy bone scintigram, PET scan
Other surveillance programs should be sought beyond the 5th year
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survival benefit of PAND when lymphadenopathy
restricted to the No. 16 a2–b1 region is found by preop-
erative imaging studies.
As a multidisciplinary treatment for this population, a
treatment strategy of two courses of neoadjuvant
chemotherapy with S-1 ? cisplatin followed by PAND was
explored in a phase II trial. Patients with bulky nodal disease
with or without lymphadenopathy restricted to the No. 16 a2–
b1 region were eligible, and peritoneal metastasis as well as
the CY1 status had to be ruled out by staging laparoscopy
prior to registration. Since a 5-year survival rate of 53 % was
reported in this trial [37], this treatment strategy could be
recommended for institutions with sufficient expertise in
PAND. On the other hand, there are arguments that a 5-year
survival rate of around 10 % can be achieved by
chemotherapy when the para-aortic lymph node metastasis is
the only factor that renders patients incurable [38, 39].
However, these retrospective studies are known to include
patients who eventually underwent surgery after responding
to the chemotherapy and may at least partially reflect the
benefit of the multidisciplinary approach.
CQ2. How should gastric cancer with hepatic metastases be
treated?
Answer A multidisciplinary approach including surgery
with curative intent could be proposed when the number of
metastatic nodules is small, provided other non-curative
factors are absent.
Hepatic metastases from gastric cancer are classified as
M1, and surgery with curative intent is not indicated
according to the treatment algorithm of the current guide-
lines (refer to ‘‘Algorithm of standard treatments to be
recommended in clinical practice’’).
Hepatic metastases from gastric cancer are often deemed
unresectable since they are liable to be found as multiple
nodules distributed to both hepatic lobes and are likely to be
accompanied with metastatic lesions outside of the liver. No
prospective trial exploring a benefit of hepatectomy has been
conducted, and only retrospective analyses of small cohorts
collected over several decades mostly as single-institution
studies [40–42] are available. However, 5-year survival rates
ranging from 10 to 40 % have been reported from these
studies, and one cannot deny a possibility that hepatectomy
results in long-term survival among highly selected patients.
Solitary metastasis or a small number of metastatic nodules
has been highlighted as a favorable prognostic factor in most
of the studies [43]. Given the recent advances in imaging
studies, and the fact the diagnosis of solitary metastasis
could be unreliable in older cases, hepatectomy may be
considered for patients with a small number of metastatic
nodules, and not restricted to a solitary tumor, provided that
there is no other non-curative factor. Since there was no
agreement on whether the synchronous metastases fare
better than metachronous metastases, surgery could also be
considered for recurrences in the liver if they fulfill the
conditions mentioned above. Most patients eventually suffer
from recurrences, however, and perioperative chemotherapy
could be recommended for the population that had not been
treated by adjuvant chemotherapy prior to detection of the
hepatic metastases. Evidence on which chemotherapeutic
regimen can be recommended in this particular setting,
however, is totally lacking.
CQ3. How should gastric cancer with positive peritoneal
cytology (CY1) be treated? Could there be any therapeutic
proposal for patients who underwent gastrectomy and were
found afterwards to have been CY1 (in some institutions,
results of the cytologic examination are available only after
surgery in case the sample was collected at surgery)?
Answer Multidisciplinary treatment including standard
gastrectomy can be proposed for patients with no other
non-curative factors. If the CY1 status was revealed after
surgery, postoperative treatment with S-1 can be recom-
mended as the tentative standard.
In Japan, peritoneal washing samples are usually col-
lected during surgery for cytologic examination to detect
free cancer cells. Free cancer cells in the peritoneal cavity
(CY1) are classified as M1, and surgery with curative intent
is not indicated according to the treatment algorithm of the
current guidelines (refer to ‘‘Algorithm of standard treat-
ments to be recommended in clinical practice’’). However,
patients with CY1 status are often treated by standard
gastrectomy in the absence of other no-curative factors. The
outcome of these patients had originally been dismal with a
median survival time of approximately 12 months and
5-year survival rate of 7.8 %, but such data often included
patients who were treated with surgery alone [44].
More recently, a prospective phase II study was con-
ducted in which technically resectable cancer with CY1 as
the only non-curative factor (patients with minimal and
resectable peritoneal deposits included) was treated by
standard gastrectomy followed by S-1 monotherapy until
disease progression. The median recurrence-free and
overall survival time in this study were 376 and 705 days,
and 5-year recurrence-free and overall survival rates were
21 and 26 %, respectively [45]. In addition, a single-in-
stitution retrospective study of 120 CY1 patients who
underwent surgery followed by S-1 monotherapy revealed
a 5-year survival rate of 26.6 % [46], which was compat-
ible with the trial result. These results are far better than the
results obtained before S-1 became available and are
equivalent to that of a series of curatively resected linitis
plastica-type cancers, which often recur as peritoneal dis-
ease [47]. Furthermore, CY1 patients are deemed eligible
for JCOG0501, a phase III trial to explore neoadjuvant
chemotherapy by S-1 ? cisplatin for scirrhous type gastric
cancer in which the standard treatment arm consists of
standard gastrectomy followed by S-1.
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These facts indicate that CY1 patients could be indi-
cated for the strategy consisting of standard gastrectomy
and perioperative chemotherapy. In addition, S-1
monotherapy could be recommended for patients whose
CY1 status was informed after gastrectomy. On the other
hand, if the information on CY status was available prior to
surgery, a chemotherapy-first strategy could be taken
whereby only patients whose cytology status turned nega-
tive could be indicated for surgery [48, 49]. However,
details of the optimal multidisciplinary treatment strategy
in this setting, including the chemotherapeutic regimen to
be used and the number of cycles to be delivered, remain to
be elucidated in future clinical trials.
CQ4. Which chemotherapeutic regimen is recommended
when recurrence was detected during or within 6 months
from completion of the postoperative adjuvant
chemotherapy with S-1?
Answer Although no evidence to recommend any particular
regimen exists, most physicians would avoid monotherapy
with S-1 for second-line chemotherapy.
Postoperative adjuvant chemotherapy with S-1 has been
established as a standard of care for p-Stage II/III gastric
cancer by the ACTS-GC trial. However, the treatment for
patients who had recurrent disease after the adjuvant
treatment remains to be elucidated.
The response rate of treatment by S-1 ? cisplatin is
reportedly low (5 %) for patients who had recurrence
within 6 months from completion of the S-1 adjuvant
therapy when compared with the response rate for recur-
rences after 6 months from the completion (37.5 %) [50].
This result, found in a multi-institutional retrospective
analysis, suggests that cancers that recur during or early
after completion of an adjuvant chemotherapy are resistant
to the drug used in that chemotherapy. On the other hand, a
retrospective analysis of the patients registered for the
ACTS-GC study revealed that patients who received S-1
among other drugs in salvage line treatments survived
longer after recurrence than those who did not receive S-1,
regardless of the time interval between the adjuvant
chemotherapy and recurrence. However, results of this
study will have to be interpreted with caution since the
study suffers from several biases in the background of the
patients such as whether oral food intake was possible
(patients who did not receive S-1 after recurrence might
have been those with bowel obstruction who were unable
to eat and suffered from poor performance status).
In treatment for colorectal cancer during the era of
adjuvant chemotherapy with 5FU alone, drugs used in the
salvage line treatment depended on the time interval
between the completion of the adjuvant chemotherapy and
recurrence. New regimens have been developed as first-line
therapy for patients who had recurrence more than
6 months after completion of the adjuvant treatment and as
second line for those who had recurrence during or within
6 months of the adjuvant therapy.
The same rule has been applied for gastric cancer, and
patients with late recurrence after adjuvant treatment have
been deemed eligible for clinical trials exploring a first-line
treatment, whereas those with early recurrences were reg-
istered in clinical trials for the second-line treatment.
Thus, patients with recurrences during or early after
completion of the adjuvant treatment are considered as
targets of second-line treatments, and S-1 monotherapy is
usually avoided for this population. However, there is
currently no evidence to recommend any specific regimen
for this setting.
CQ5. Which chemotherapeutic regimen is recommended
for patients suffering from either bowel obstruction or
massive ascites due to severe peritoneal metastases?
Answer The indication for chemotherapy itself should be
decided discreetly, taking into consideration the general
status of the patient. Drugs with mild toxicity profiles such
as infusional 5-fluorouracil and paclitaxel could be con-
sidered as the candidates.
Standard of care has not been established for this pop-
ulation since the patients have not been eligible for most
clinical trials for advanced/metastatic gastric cancer. Most
patients in this population suffer from poor general status
and will not tolerate the S-1 ? cisplatin combination.
Benefit for delivering chemotherapy should be weighed
carefully against the risk, and best supportive care should
be considered as an alternative.
The JCOG0106 study was one of the few in which only
patients with peritoneal metastases detected by imaging
studies such as CT and barium enema were eligible. In this
trial, sequential therapy combining methotrexate ? 5FU,
which had been considered promising in this setting, was
explored with continuous intravenous administration of
5FU (5FUci) as a control, but failed to show a survival
benefit, while infusional 5FU was found to be less toxic
[51]. Moreover, 5FUci enabled oral food intake in 41 % (7/
27) of patients who had been unable to eat at the time of
entry to the trial. Thus, 5FUci will be the current first
choice for patients with bowel obstruction due to peritoneal
metastases, but its effect on massive ascites remains elu-
sive. On the other hand, another domestic phase III trial
(ISO-5FU10) has shown non-inferiority of the
5FU ? leucovorin (LV) combination against S-1 [52].
Thus, 5FU ? LV, which can be delivered in the outpatient
clinic, is another option for patients with relatively good
general status.
In a phase II trial exploring weekly administration of
paclitaxel in gastric cancer patients with ascites, improve-
ment in the volume of ascites evaluated by a five-point
measurement using the CT image was seen in 39 % (25/64)
of the patients [53]. In a randomized phase II trial
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comparing second-line treatment by weekly administration
of paclitaxel with the best available 5FU (either 5FUci or
MTX ? 5FU, which was not used in the first-line treat-
ment) in patients with peritoneal metastases, a benefit in
progression-free survival was proven, but no difference
was detected in overall survival. However, paclitaxel was
associated with a more favorable toxicity profile [54].
These results indicate that weekly paclitaxel can be con-
sidered for patients with severe peritoneal disease in both
the first- and second-line setting. In addition, a phase II trial
of the FLTAX regimen, which is a combination of pacli-
taxel with 5FU ? LV, has shown that this combination
reduced ascites in 44 % of patients [55]. Further evidence
through a randomized comparison of the combination with
a single-agent treatment is awaited.
CQ6 Which chemotherapeutic regimen is recommended
for elderly patients with unresectable/advanced gastric
cancer?
Answer S-1 ? cisplatin could be recommended for fit
patients, but utmost care should be taken since the elderly
patients are generally vulnerable to the adverse events. S-1
monotherapy could be selected for more frail patients.
Although S-1 ? cisplatin is the standard first-line treat-
ment for unresectable/recurrent gastric cancer in Japan, only
patients up to 74 years of age were eligible for the SPIRITS
trial that generated this evidence, and only 17 % (50/298) of
patients registered for this trial were actually 70 years of age
or older. In a subset analysis stratified by age, the hazard ratio
of treatment by S-1 ? cisplatin versus S-1monotherapywas
0.75 (95 % CI 0.61–0.92) for patients under 60 years of age
(n = 111) as opposed to 0.98 (95 % CI 0.82–1.17) for those
between 60 and 69 and 0.95 (95 % CI 0.71–1.27) for those
between 70 and 74 [15]. Thus, a benefit of adding cisplatin is
unclear for the elderly population. In fact, there was no dif-
ference in survival between patients treated by S-1 ? cis-
platin and those treated by S-1 monotherapy in a
retrospective study of the elderly population of C70 years of
age, despite the apparent bias that the seemingly more fit
patients were selected to receive the combination therapy
[56]. Furthermore, a rather favorable outcome through S-1
monotherapy was reported in a cohort of patients C75 years
of age in a prospective phase II trial focusing on elderly
patients [57].
In short, regarding chemotherapy for advanced/meta-
static gastric cancer, the evidence generated by the general
population is unlikely to be directly applicable to elderly
patients. That said, it may still be inadequate to estimate
the tolerability of elderly patients to chemotherapy based
only on chronological age without taking into account the
major organ functions, comorbidities and past history.
Unfortunately, however, a method to comprehensively
evaluate the vulnerability of each aged individual has not
been established.
Further evidence through clinical trials is needed for
various decision-makings when treating elderly patients
with gastric cancer. Until then, whether or not to deliver
S-1 ? cisplatin to these patients will have to be decided on
a patient-by-patient basis based on the experience of each
physician. Such decision will have to be based on the
general condition of the patient with particular attention to
the renal and cardiac function, always bearing in mind that
S-1 monotherapy is quite reasonable as an alternative. Even
after the treatment has started, the patient will have to be
monitored with upmost care with attention paid not only to
severe adverse events but also to anorexia, stomatitis and
diarrhea, which could be particularly debilitating for
elderly patients.
CQ7. Which chemotherapeutic regimen is recommended as
a second-line treatment for HER2-positive gastric cancer?
Answer The taxanes or irinotecan can be recommended as
in the case of HER2-negative cancer. However, in case a
trastuzumab-containing regimen was not given as a first-
line treatment, a combination of weekly paclitaxel and
trastuzumab could be selected.
A trastuzumab-containing regimen is recommended for
the first-line treatment of HER2-positive gastric cancer as a
result of the ToGA trial [17]. There is no evidence to
recommend any specific regimen for the specific cohort of
HER2-positive patients who progressed during or after the
trastuzumab-containing regimen. Either the taxanes or
irinotecan could be selected as in the case of second-line
treatment for HER2-negative gastric cancer.
On the other hand, a promising response rate of 37.0 %
(95 % CI 23.2–52.5) and disease control rate of 82.6 %
(95 % CI 68.2–92.2) were reported in a phase II trial
exploring paclitaxel (weekly administration) ? trastuzu-
mab (JFMC45-1102 trial) for 46 evaluable patients with
HER2-positive gastric cancer who were pretreated with a
regimen that did not contain trastuzumab [58]. However,
results of this trial will have to be interpreted with care for
the following reasons: (1) Patients registered for this trial
were not a typical cohort that receives second-line
chemotherapy after the first-line treatment with a combi-
nation of fluorouracil and platinum agent in that 12 patients
(26 %) were pretreated only with postoperative adjuvant
chemotherapy while 5 patients (11 %) had already been
treated with two lines of treatment; (2) although post-
treatment cardiac function tests revealed that only one
patient showed[10 % reduction in the left ventricular
ejection fraction, other safety data are currently under
analysis and have not been published.
There is currently no evidence in support of efficacy or
safety for continuing with trastuzumab in case the patient
was pretreated with a trastuzumab-containing regimen
(trastuzumab beyond progression).
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